Thrombosis research最新文献

{"title":"The efficacy and safety of andexanet alfa in the treatment of anticoagulation-related major bleedings: An Italian perspective","authors":"Paolo Simioni , Alessandro Cipriano , Armando D'Angelo , Gianfranco Giannasi , Giorgio Ricci , Elena Campello , Beniamino Susi , Vincenzo Andreone , Paolo Candelaresi","doi":"10.1016/j.thromres.2024.109241","DOIUrl":"10.1016/j.thromres.2024.109241","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109241"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thromboinflammation in ischemic cerebrovascular patients with the JAK2V617F mutation","authors":"Marie Hvelplund Kristiansen ,&nbsp;Morten Kranker Larsen ,&nbsp;Laura Massarenti ,&nbsp;Vibe Skov ,&nbsp;Lasse Kjær ,&nbsp;Christian Enevold ,&nbsp;Sisse Rye Ostrowski ,&nbsp;Claus Henrik Nielsen ,&nbsp;Hans Carl Hasselbalch ,&nbsp;Troels Wienecke","doi":"10.1016/j.thromres.2024.109236","DOIUrl":"10.1016/j.thromres.2024.109236","url":null,"abstract":"<div><h3>Background</h3><div>The <em>JAK2V617F</em> mutation is a driver of Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) and is also implicated in cardiovascular diseases. Thrombosis in MPN involves <em>JAK2V617F</em>-associated platelet activation and endothelial dysfunction, all potentially influenced by chronic inflammation. Whether the mutation affects thromboinflammatory markers similarly in non-MPN patients remains unclear.</div></div><div><h3>Method</h3><div>We conducted a study involving 63 ischemic cerebrovascular patients with the <em>JAK2V617F</em> mutation, matched with 63 patients without the mutation. Serum samples were analyzed for 12 thromboinflammatory markers during the acute phase and at three months follow-up.</div></div><div><h3>Results</h3><div>Overall, there was no significant difference in thromboinflammatory markers between cases and controls. However, subgroup analysis of patients with a <em>JAK2V617F</em> allele burden ≥1 % (n = 15) showed higher levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) at baseline (p = 0.018), and elevated Interleukin-10 (IL-10) (p = 0.004) and Tumor Necrosis Factor α (TNF-α) (p = 0.018) at follow-up compared to controls. Regression analysis revealed an association between higher <em>JAK2V617F</em> allele burden and increased VCAM-1 at baseline (p &lt; 0.001), and higher VCAM-1 (p = 0.012), IL-10 (p = 0.003), and TNF-α (p = 0.034) at follow-up.</div></div><div><h3>Conclusion</h3><div>In ischemic cerebrovascular patients, the <em>JAK2V617F</em> mutation is associated with elevated markers of endothelial dysfunction and chronic inflammation. This underscores the role of inflammation in thrombosis driven by the <em>JAK2V617F</em> mutation.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109236"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142802298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of hypofibrinolysis on clinical outcomes of patients with septic disseminated intravascular coagulation","authors":"Hiroyuki Koami,&nbsp;Yuichiro Sakamoto,&nbsp;Yuri Hirota,&nbsp;Akira Sasaki,&nbsp;Hirotaka Ogawa,&nbsp;Yutaro Furukawa,&nbsp;Ayaka Matsuoka,&nbsp;Kota Shinada,&nbsp;Kento Nakayama,&nbsp;Ryota Sakurai,&nbsp;Sachiko Iwanaga,&nbsp;Takayuki Onohara,&nbsp;Shogo Narumi,&nbsp;Mayuko Koba","doi":"10.1016/j.thromres.2024.109235","DOIUrl":"10.1016/j.thromres.2024.109235","url":null,"abstract":"<div><h3>Background</h3><div>This study investigated the utility of thromboelastometry (ROTEM) in assessing hypofibrinolysis among septic patients, specifically the association of hypofibrinolysis, as determined by ROTEM, with septic disseminated intravascular coagulation (DIC), organ dysfunction, and clinical outcomes.</div></div><div><h3>Methods</h3><div>This single-center, retrospective analysis included adult septic patients admitted to Saga University Hospital from 2013 to 2017, with available ROTEM data. Hypofibrinolysis was assessed using the lysis index at 60 min (LI60) in extrinsic thromboelastometry (EXTEM). Based on their LI60 values, patients were classified into three groups: Hyper (LI60 ≤ 85), Normal (LI60 86–96), and Hypo (LI60 ≥ 97).</div></div><div><h3>Results</h3><div>Among the 63 cases analyzed, the Hypo group showed significantly higher APACHEII and SOFA scores than the Normal group, indicating greater disease severity. Similarly, DIC and sepsis-induced coagulopathy (SIC) scores were notably higher in the Hypo group. The diagnostic performance of LI60 for ISTH-overt DIC showed an area under the curve (AUC) of 0.954, with an optimal cutoff value of 97 %, achieving 100 % sensitivity and 83.3 % specificity. The odds ratio for ISTH-overt DIC was 2.894, indicating a strong association between elevated LI60 and occurrence of DIC. Hypofibrinolysis predicted 28-day mortality and high SOFA scores (≥ 10) with high specificity and negative predictive value (NPV). A Kaplan-Meier curve revealed that the Hypo Group showed significantly worse clinical outcomes than the Normal and Hyper groups.</div></div><div><h3>Conclusion</h3><div>For septic patients, fibrinolysis suppression presenting as “hypofibrinolysis” (elevated LI60) is associated with poor prognosis and risk of higher organ dysfunction. Moreover, it is a significant predictor of adverse clinical outcomes in sepsis.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109235"},"PeriodicalIF":3.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PDPN/CLEC-2 axis modulates megakaryocyte subtypes in a hematopoietic stem cell-regulating megakaryocyte-dominant manner","authors":"Rikuto Nara ,&nbsp;Hinako Notoh ,&nbsp;Tomoyuki Sasaki ,&nbsp;Nagaharu Tsukiji ,&nbsp;Toshiaki Shirai ,&nbsp;Ayuka Kamata ,&nbsp;Nobuaki Suzuki ,&nbsp;Atsuo Suzuki ,&nbsp;Shuichi Okamoto ,&nbsp;Takeshi Kanematsu ,&nbsp;Naruko Suzuki ,&nbsp;Akira Katsumi ,&nbsp;Tetsuhito Kojima ,&nbsp;Katsue Suzuki-Inoue ,&nbsp;Tadashi Matsushita ,&nbsp;Shogo Tamura","doi":"10.1016/j.thromres.2024.109230","DOIUrl":"10.1016/j.thromres.2024.109230","url":null,"abstract":"<div><h3>Introduction</h3><div>Megakaryocytes are classified into several subtypes including LSP1-positive immune-skewed, MYLK4-positive hematopoietic stem cell (HSC)-regulating, and BMAL1-positive platelet-producing megakaryocytes. Podoplanin (PDPN)-expressing stromal cells generate a microenvironment that promotes megakaryopoiesis in the bone marrow. In this context, PDPN interacts with C-type lectin-like receptor-2 (CLEC-2) on megakaryocyte progenitors, which induces megakaryocyte proliferation. However, the megakaryocyte subtypes developed by the regulation of the PDPN/CLEC-2 axis have not yet been elucidated.</div></div><div><h3>Materials and methods</h3><div>We established an immortalized bone marrow PDPN-expressing stromal cell line and a PDPN-knockout line (PDPN WT and KO feeder cells, respectively). Bone marrow hematopoietic progenitors were committed to megakaryocytes in co-culture with PDPN WT or KO feeder cells. The number and ploidy of megakaryocytes, resultant platelets, and the polarization of megakaryocyte subtypes were investigated.</div></div><div><h3>Results</h3><div>The number of megakaryocytes was significantly increased in the co-culture with PDPN WT feeder cells compared to that with PDPN KO feeder cells. The megakaryocytes on the PDPN WT and KO feeders showed their main ploidy at 16 N∼32 N and 8 N∼16 N, respectively. The number of platelets was decreased in the co-culture with the PDPN WT feeder compared to that in the co-culture with the PDPN KO feeder. For each megakaryocyte subtype, the percentage of MYLK4-positive megakaryocytes significantly increased and the percentage of BMAL1-positive megakaryocytes significantly decreased when co-cultured with the PDPN WT feeder. These results were also confirmed in the co-culture of CLEC-2 conditional KO megakaryocytes with PDPN WT feeder cells.</div></div><div><h3>Conclusion</h3><div>The PDPN/CLEC-2 axis modulates megakaryocyte subtype differentiation, with a predominance of HSC-regulating megakaryocytes.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109230"},"PeriodicalIF":3.7,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142745660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of low-dose acetylsalicylic acid for the prevention of thromboembolic events in individuals positive for antiphospholipid antibodies: A systematic review and meta-analysis","authors":"Federica De Pascali ,&nbsp;Yulia Aleksandrovna Filippova ,&nbsp;Marco P. Donadini ,&nbsp;Vittorio Pengo ,&nbsp;Alessandro Squizzato","doi":"10.1016/j.thromres.2024.109225","DOIUrl":"10.1016/j.thromres.2024.109225","url":null,"abstract":"<div><h3>Background</h3><div>Anti-Phospholipid Antibodies (aPL) are autoantibodies predisposing to an increased risk of thrombotic events. The net clinical benefit of antithrombotic prophylaxis in aPL carriers is still unclear. We performed a systematic review to assess the efficacy and safety of antiplatelet drugs for the primary prevention of thrombotic events in aPL carriers.</div></div><div><h3>Methods</h3><div>Studies were identified by electronic search of MEDLINE and EMBASE database until May 2023. The differences in the outcomes among groups were estimated as pooled odds ratio (OR) and corresponding 95 % confidence interval (CI). Statistical heterogeneity was evaluated using the I2 statistic.</div></div><div><h3>Results</h3><div>1056 participants were included in 10 studies, 2 RCTs and 8 cohorts. Low-dose acetylsalicylic acid (LDA) was the antiplatelet drug in treated patients. Thrombotic events were significantly reduced in the LDA group compared to the control group [OR 0.46 (95 % CI 0.30–0.71), I2 27%, fixed-effects model]. Arterial thrombotic events were significantly reduced in the LDA group compared to the control group [OR 0.47 (95 % CI 0.26–0.86), I2 0%, fixed-effects model]. Venous thrombotic events were significantly reduced in the LDA group compared to the control group [OR 0.44 (95 % CI 0.21–0.89, I2 1%, fixed-effects model]. No major bleedings occurred in the five studies reporting them.</div></div><div><h3>Conclusions</h3><div>aPL carriers receiving long-term LDA had a significant reduction of thrombotic events, without a significant increase of the risk of major bleeding. It remains unclear if LDA has the same benefit/risk profile in all aPL profile, i.e. single, double, or triple positivity.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109225"},"PeriodicalIF":3.7,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142702847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus-associated hypoprothrombinemia syndrome in children: Differences between post-infectious and autoimmune forms","authors":"Zighed Hanna ,&nbsp;Huguenin Yoann ,&nbsp;Blanc Laurence ,&nbsp;Valentin Jean-Baptiste ,&nbsp;Babuty Antoine ,&nbsp;Cussac Vincent ,&nbsp;Heritier Sebastien ,&nbsp;Biron-Andreani Christine ,&nbsp;Jeziorski Eric ,&nbsp;Moulis Lionel ,&nbsp;Harroche Annie ,&nbsp;Theron Alexandre","doi":"10.1016/j.thromres.2024.109231","DOIUrl":"10.1016/j.thromres.2024.109231","url":null,"abstract":"<div><h3>Introduction</h3><div>Lupus-anticoagulant hypoprothrombinemia syndrome (LAHS) is a rare but potentially serious condition. LAHS can be of post-infectious (PI) or autoimmune (AI) origin. However, there is currently no clear data available on the differences between these two forms.</div></div><div><h3>Method</h3><div>A retrospective multicenter study of cases in France was performed, followed by a review of cases in the literature.</div></div><div><h3>Result</h3><div>A total of 84 patients were included in the study. Seventeen patients were selected from the French cohort, and 67 were selected from a systematic review of the literature. 95 % of patients presented with hemorrhagic symptoms, with nearly half of these cases being severe. PI or AI context was identified in 33 % and 53 % of cases. 54 % of patients were treated with corticosteroids, and 30 % received immunomodulatory therapy. Thrombopenia and lower factor V were associated with a higher risk of bleeding. The AI group consisted of older children and exhibited significantly more severe bleeding (<em>p</em> &lt; 0.001). The treatment was more frequent and intensive, and the relapse rate was higher in the AI group (p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Post-infectious forms are transient and associated with a low risk of serious hemorrhage. The treatment must be adapted according to the clinical and biological context.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109231"},"PeriodicalIF":3.7,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142702848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of recurrent venous thromboembolism according to location of metastasis in patients with cancer-associated thrombosis. A cohort study","authors":"Victor Garcia-Garcia ,&nbsp;Maria Barca-Hernando ,&nbsp;Sergio Lopez-Ruz ,&nbsp;Carmen Rosa-Linares ,&nbsp;Teresa Elias-Hernandez ,&nbsp;Remedios Otero-Candelera ,&nbsp;David Gutierrez-Campos ,&nbsp;Henry Andrade-Ruiz ,&nbsp;Marc Carrier ,&nbsp;Luis Jara-Palomares","doi":"10.1016/j.thromres.2024.109228","DOIUrl":"10.1016/j.thromres.2024.109228","url":null,"abstract":"<div><h3>Background</h3><div>Risk of VTE recurrence (VTEr) in patients with cancer-associated thrombosis (CAT) is high. Cancer-related risk factors for VTEr have been studied, but information about the importance of location of metastasis is scarce.</div></div><div><h3>Objectives</h3><div>1) Evaluate rate of VTEr in CAT patients according to location of metastasis, and 2) Identify variables associated to VTEr during long-term follow-up.</div></div><div><h3>Methods</h3><div>A retrospective, single-center, non-interventional study of consecutives patients with CAT conducted between 2007 and 2022. Haematological neoplasms were excluded.</div></div><div><h3>Results</h3><div>Among 1248 patients with CAT (age 64.1 ± 12.8 years; 48.2 % female) followed-up for 13.19 months (p25–75, 5.6–26.9) there were 141 VTEr. The rate of VTE recurrence in patients without and with metastasis were 4.72 per 100 patient-years (95%CI: 3.66–6) and 10.05 per 100 patient-years (95 % CI: 7.89–12.61), respectively. The metastases locations associated with VTEr, compared to those without metastasis, were lung (rate ratio [RR]: 2.21; 95 % CI: 1.42–3.43), liver (RR: 2.02; 95%CI: 1.26–3.24), pancreas (RR: 6.21; 95 % CI: 1.52–25.35), pleura (RR: 2.93; 95%CI: 1.58–5.41), bone (RR: 2.16; 95 % CI: 1.29–3.64) and adrenal (RR: 6.18; 95%CI: 2.97–12.86). Multivariate analysis of variables associated with VTEr beyond 12 months were male sex (hazard ratio [HR] 1.54, 95%CI: 1.08–2.19), ECOG performance status &gt;1 (HR 1.74, 95%CI: 1.03–2.94), metastasis in 1–2 locations (HR 2.38, 95%CI: 1.68–3.37) and metastasis in &gt;2 locations (HR 3.88, 95%CI: 1.68–8.98).</div></div><div><h3>Conclusions</h3><div>The rate of VTEr differs according to the location of metastasis. We identified variables related to VTEr during long-term follow-up which may help clinicians decide whether to continue anticoagulation.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109228"},"PeriodicalIF":3.7,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142757221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risks of major arterial and venous thrombotic diseases after hospitalisation for influenza, pneumonia, and COVID-19: A population-wide cohort in 2.6 million people in Wales","authors":"Spencer Keene ,&nbsp;Hoda Abbasizanjani ,&nbsp;Fatemeh Torabi ,&nbsp;Rochelle Knight ,&nbsp;Venexia Walker ,&nbsp;Elena Raffetti ,&nbsp;Genevieve Cezard ,&nbsp;Samantha Ip ,&nbsp;Alexia Sampri ,&nbsp;Thomas Bolton ,&nbsp;Rachel Denholm ,&nbsp;Kamlesh Khunti ,&nbsp;Ashley Akbari ,&nbsp;Jennifer Quint ,&nbsp;Spiros Denaxas ,&nbsp;Cathie Sudlow ,&nbsp;Emanuele Di Angelantonio ,&nbsp;Jonathan A.C. Sterne ,&nbsp;Angela Wood ,&nbsp;William N. Whiteley","doi":"10.1016/j.thromres.2024.109213","DOIUrl":"10.1016/j.thromres.2024.109213","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;Pneumonia, influenza, COVID-19, and other common infections might increase the risk of thrombotic events acutely through an interaction between inflammation and the thrombotic system. The long-term risks of arterial and venous thrombotic events following hospitalisation for COVID-19 and hospitalisation for pneumonia or influenza are unclear.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;div&gt;In a population-wide cohort of linked Welsh health data of adults, we calculated the incidence of arterial and venous thrombosis after hospitalisation for COVID-19 (2020−2021). We then compared this post-hospitalisation incidence with the incidence prior to COVID-19 hospitalisation in the same individuals, and with the incidence in individuals who were never hospitalised for COVID-19. We then repeated this analysis for hospitalisation for pneumonia or influenza in a separate cohort (2016–2019). We estimated adjusted hazard ratios (aHRs) in separate time periods starting from the date of the first infection that resulted in hospitalisation (day 0, 1 to 7 days, 2 to 4 weeks, 5 to 16 weeks, and 17 to 75 weeks) using time-varying Cox regression. Confounders included age, sex, smoking status, obesity, deprivation (fifths of Welsh Index of Multiple Deprivation), rural or urban setting, care home attendance, Elixhauser comorbidity index, surgery in the last year, medications (e.g. lipid-lowering and antiplatelet/anticoagulant use), hypertension and/or hypertensive medication use, and past medical history of chronic kidney disease, diabetes, chronic obstructive pulmonary disease, dementia, cancer, or any CVD.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;For the first arterial thrombosis, the aHRs were 3.80 (95 % CI: 2.50–5.77) between days 1–7, 5.24 (4.21–6.51) between weeks 2–4, 2.12 (1.72–2.60) between weeks 5–16, and 1.60 (1.38–1.86) between weeks 17–75 after hospitalisation for COVID-19. The corresponding aHRs after hospitalisation for pneumonia/influenza were: 5.42 (4.35–6.75), 3.87 (3.32–4.49), 1.96 (1.74–2.21), and 1.41 (1.30–1.53).&lt;/div&gt;&lt;div&gt;For first venous thrombosis, aHRs were 7.47 (3.56–15.7) between days 1–7, 22.6 (17.5–29.1) between weeks 2–4, 6.58 (4.98–8.68) between weeks 5–16, and 2.25 (1.67–3.02) between weeks 17–75 after hospitalisation for COVID-19. The corresponding aHRs after hospitalisation for pneumonia/influenza were: 15.1 (10.3–22.0), 11.8 (9.23–15.1), 5.80 (4.75–7.08), and 1.89 (1.57–2.29).&lt;/div&gt;&lt;div&gt;Excess risk was highest in individuals aged ≥60 years, in whom we estimated 2,700 and 2,320 additional arterial and 1,270 and 840 additional venous events after 100,000 hospitalisations for COVID-19 and pneumonia/influenza, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Both hospitalisation for COVID-19 and pneumonia/influenza increase the risk of arterial and venous thrombosis. Preventative healthcare policies are needed for cardiovascular risk factor management, vaccination, and anticoagulation in high-risk patient","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109213"},"PeriodicalIF":3.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142720729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DOAC Score for prediction of major bleeding in patients with venous thromboembolism: Findings from the RIETE registry","authors":"Paolo Prandoni ,&nbsp;Franca Bilora ,&nbsp;Raffaele Pesavento ,&nbsp;José María Pedrajas ,&nbsp;José Luis Fernández-Reyes ,&nbsp;Covadonga Gómez-Cuervo ,&nbsp;Aurora Villalobos ,&nbsp;Alicia Alda-Lozano ,&nbsp;Paolo Simioni ,&nbsp;Manuel Monreal ,&nbsp;RIETE Investigators","doi":"10.1016/j.thromres.2024.109226","DOIUrl":"10.1016/j.thromres.2024.109226","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109226"},"PeriodicalIF":3.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The contact system in chronic kidney disease and hemodialysis – A cross-sectional study","authors":"Yaseelan Palarasah ,&nbsp;Rikke Borg ,&nbsp;Else-Marie Bladbjerg ,&nbsp;Stephanie Thuy Duong Pham ,&nbsp;Anna Mejldal ,&nbsp;Christian Nielsen ,&nbsp;Erik Bo Pedersen ,&nbsp;Per Bruno Jensen ,&nbsp;Helle Charlotte Thiesson ,&nbsp;Katrine Pilely","doi":"10.1016/j.thromres.2024.109229","DOIUrl":"10.1016/j.thromres.2024.109229","url":null,"abstract":"<div><h3>Background and hypothesis</h3><div>The contact system (CAS) is a part of both the immune system and the coagulation system. The involvement of the CAS in chronic kidney disease (CKD) and hemodialysis (HD) has been documented, yet conflicting findings have hindered a comprehensive understanding. This study aimed to investigate whether CAS activation occurs in patients with chronic kidney failure undergoing HD compared with those undergoing peritoneal dialysis (PD), patients with CKD not receiving replacement therapy, or healthy controls and to assess the impact of HD on CAS from pre- to post-dialysis during a single session of HD.</div></div><div><h3>Methods</h3><div>In this cross-sectional study, blood samples from HD patients (<em>n</em> = 106), PD patients (<em>n</em> = 40), CKD patients (<em>n</em> = 60), and healthy control subjects (<em>n</em> = 80) were analyzed. The levels of CAS components, including factor XII, prekallikrein, high-molecular-weight kininogen (HK), cleaved HK (cHK), and C1-inhibitor, and functional kallikrein generation were determined. Among HD patients, CAS measures were evaluated both pre- and post-dialysis. Linear regression models and linear mixed models were employed to analyze associations and changes.</div></div><div><h3>Results</h3><div>HD patients had altered levels of prekallikrein, factor XII, and cHK compared with PD patients, CKD patients, and the healthy control group. Moreover, HD patients demonstrated increased levels of C1-inhibitor and reduced functional kallikrein generation, a pattern also observed in PD patients and, to a lesser degree, in CKD patients when compared with healthy controls. Notably, no CAS activation was detected during HD.</div></div><div><h3>Conclusions</h3><div>Impaired kidney function, especially in patients undergoing HD or PD, was associated with reduced functional kallikrein generation and altered levels of CAS components, implying continuous CAS activation in CKD. There was no indication of significant activation of factor XII-mediated CAS during HD. The role of CAS in CKD, independently of dialysis, should be addressed in future research.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"245 ","pages":"Article 109229"},"PeriodicalIF":3.7,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}